On the 8th in the morning, Alteogen shares rebounded in the 2% range. The move came after a securities firm analysis said the impact of an injunction banning sales, which triggered a more than 12% plunge in the previous session, would be limited.
As of 9:28 a.m. that day, Alteogen was trading on the KOSDAQ market at 467,000 won, up 10,500 won (2.3%) from the previous session.
Kim Seon-a, a researcher at Hana Securities, said, "An injunction banning sales of Keytruda SC, filed by the German company Halozyme, has been granted," and noted, "What needs to be clearly understood about this issue is that the granting of an injunction in Germany is entirely separate from any determination on the validity or invalidity of patent rights."
She added, "This order cannot affect sales in the United States (territoriality), and countries outside Europe make independent determinations," and explained, "The impact is limited to Germany, and German sales account for only the 2% range of total Keytruda sales."